English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Recent recommendations for treatment of rheumatoid arthritis (RA) include “treat-to-target” with a “primary target…a state of clinical remission”1. Remission is now a realistic target in RA, because patient status is substantially better than in previous decades in most developed countries2. Capacity to induce remission may be an effective rationale for support of aggressive treatment with expensive therapies to insurance company and government payers.The concept of “treat-to-target” was developed over the years in other chronic diseases, notably hypertension3,4, diabetes5, and hyperlipidemia6. The basis of treat-to-target was not “remission,” a state that may often be possible, but as in RA, usually requires continued lifelong medication. The target, in other diseases, involves “tight control” of a “gold standard” biomarker of dysregulation — elevated blood pressure, serum glucose, or serum cholesterol — to a lower level that results in improved quality of life and reduction of premature mortality rates. Such a target – not a state of remission – provides a strong rationale for aggressive treatment.RA differs substantially from hypertension, diabetes, or hyperlipidemia in that there is no single, gold standard biomarker (or any other measure) for diagnosis, management, or prognosis in all individual patients. Biomarkers are of unquestioned importance in RA to understand pathogenesis and develop new therapies: Biological agents would not be available without them. However, biomarkers are limited in clinical application to diagnosis, management, and prognosis of RA:Forty percent of new patients have normal erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)7,8, and > 30% test negative for rheumatoid factor or anti-citrullinated protein antibodies (ACPA)9.Clinical decisions in RA are based more on a patient history and physical examination than on biomarkers; in contrast, biomarkers dominate clinical decisions in many … Address correspondence to Dr. Pincus; E-mail: tedpincus{at}gmail.com

the journal of rheumatology/journal of rheumatology

Documenting the Value of Care for Rheumatoid Arthritis, Analogous to Hypertension, Diabetes, and Hyperlipidemia: Is Control of Individual Patient Self-Report Measures of Global Estimate and Physical Function More Valuable Than Laboratory Tests, Radiographs, Indices, or Remission Criteria?